Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 7
1975 3
1976 2
1977 3
1978 5
1979 5
1980 7
1981 7
1982 7
1983 3
1984 4
1985 5
1986 8
1987 2
1988 3
1989 6
1990 9
1991 7
1992 8
1993 9
1994 11
1995 10
1996 12
1997 12
1998 8
1999 2
2000 3
2001 6
2002 3
2003 5
2004 3
2005 7
2006 6
2007 8
2008 4
2009 5
2010 6
2011 9
2012 6
2013 9
2014 12
2015 5
2016 8
2017 9
2018 10
2019 5
2020 4
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

291 results
Results by year
Filters applied: . Clear all
Page 1
Targeting the MAPK Pathway in KRAS-Driven Tumors.
Drosten M, Barbacid M. Drosten M, et al. Among authors: barbacid m. Cancer Cell. 2020 Apr 13;37(4):543-550. doi: 10.1016/j.ccell.2020.03.013. Cancer Cell. 2020. PMID: 32289276 Free article. Review.
Cell cycle, CDKs and cancer: a changing paradigm.
Malumbres M, Barbacid M. Malumbres M, et al. Among authors: barbacid m. Nat Rev Cancer. 2009 Mar;9(3):153-66. doi: 10.1038/nrc2602. Nat Rev Cancer. 2009. PMID: 19238148 Review.
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N. Yao Z, et al. Among authors: barbacid m. Nature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2. Nature. 2017. PMID: 28783719 Free PMC article.
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.
Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, Zhang Y, Zhang C, Rymar A, Tao A, Timaul NM, Mcgriskin R, Outmezguine NA, Zhao H, Chang Q, Qeriqi B, Barbacid M, de Stanchina E, Hyman DM, Bollag G, Rosen N. Yao Z, et al. Among authors: barbacid m. Nat Med. 2019 Feb;25(2):284-291. doi: 10.1038/s41591-018-0274-5. Epub 2018 Dec 17. Nat Med. 2019. PMID: 30559419 Free PMC article.
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
Blasco MT, Navas C, Martín-Serrano G, Graña-Castro O, Lechuga CG, Martín-Díaz L, Djurec M, Li J, Morales-Cacho L, Esteban-Burgos L, Perales-Patón J, Bousquet-Mur E, Castellano E, Jacob HKC, Cabras L, Musteanu M, Drosten M, Ortega S, Mulero F, Sainz B Jr, Dusetti N, Iovanna J, Sánchez-Bueno F, Hidalgo M, Khiabanian H, Rabadán R, Al-Shahrour F, Guerra C, Barbacid M. Blasco MT, et al. Among authors: barbacid m. Cancer Cell. 2019 Apr 15;35(4):573-587.e6. doi: 10.1016/j.ccell.2019.03.002. Epub 2019 Apr 8. Cancer Cell. 2019. PMID: 30975481 Free article.
A pericyte origin of spinal cord scar tissue.
Göritz C, Dias DO, Tomilin N, Barbacid M, Shupliakov O, Frisén J. Göritz C, et al. Among authors: barbacid m. Science. 2011 Jul 8;333(6039):238-42. doi: 10.1126/science.1203165. Science. 2011. PMID: 21737741 Free article.
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
Esteban-Burgos L, Wang H, Nieto P, Zheng J, Blanco-Aparicio C, Varela C, Gómez-López G, Fernández-García F, Sanclemente M, Guerra C, Drosten M, Galán J, Caleiras E, Martínez-Torrecuadrada J, Fajas L, Peng SB, Santamaría D, Musteanu M, Barbacid M. Esteban-Burgos L, et al. Among authors: barbacid m. Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24415-24426. doi: 10.1073/pnas.2002520117. Epub 2020 Sep 10. Proc Natl Acad Sci U S A. 2020. PMID: 32913049 Free PMC article.
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.
Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger R, Torres NM, Muniz K, Drosten M, Barbacid M, Caponigro G, Stuart D, Moebitz H, Solit DB, Abdel-Wahab O, Taylor BS, Yao Z, Rosen N. Gao Y, et al. Among authors: barbacid m. Cancer Discov. 2018 May;8(5):648-661. doi: 10.1158/2159-8290.CD-17-1452. Epub 2018 Feb 26. Cancer Discov. 2018. PMID: 29483135 Free PMC article.
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
Nokin MJ, Darbo E, Travert C, Drogat B, Lacouture A, San José S, Cabrera N, Turcq B, Prouzet-Mauleon V, Falcone M, Villanueva A, Wang H, Herfs M, Mosteiro M, Jänne PA, Pujol JL, Maraver A, Barbacid M, Nadal E, Santamaría D, Ambrogio C. Nokin MJ, et al. Among authors: barbacid m. JCI Insight. 2020 Aug 6;5(15):e137869. doi: 10.1172/jci.insight.137869. JCI Insight. 2020. PMID: 32759499 Free PMC article.
RAS oncogenes: the first 30 years.
Malumbres M, Barbacid M. Malumbres M, et al. Among authors: barbacid m. Nat Rev Cancer. 2003 Jun;3(6):459-65. doi: 10.1038/nrc1097. Nat Rev Cancer. 2003. PMID: 12778136 Review.
291 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page